These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 38156547)
1. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication. Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547 [TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Marcus L; Lemery SJ; Keegan P; Pazdur R Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650 [TBL] [Abstract][Full Text] [Related]
4. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. Lemery S; Keegan P; Pazdur R N Engl J Med; 2017 Oct; 377(15):1409-1412. PubMed ID: 29020592 [No Abstract] [Full Text] [Related]
5. The FDA Oncology Center of Excellence and precision medicine. Goldberg KB; Blumenthal GM; McKee AE; Pazdur R Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511 [TBL] [Abstract][Full Text] [Related]
6. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. Prasad V; Kaestner V; Mailankody S JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544 [No Abstract] [Full Text] [Related]
7. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA; N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544 [TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. Casak SJ; Marcus L; Fashoyin-Aje L; Mushti SL; Cheng J; Shen YL; Pierce WF; Her L; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ Clin Cancer Res; 2021 Sep; 27(17):4680-4684. PubMed ID: 33846198 [TBL] [Abstract][Full Text] [Related]
9. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585 [TBL] [Abstract][Full Text] [Related]
10. Precision medicine becomes reality-tumor type-agnostic therapy. Yan L; Zhang W Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494 [TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676 [TBL] [Abstract][Full Text] [Related]
12. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939 [TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754 [TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513 [TBL] [Abstract][Full Text] [Related]
15. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine. Seligson ND; Knepper TC; Ragg S; Walko CM Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906 [TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043 [TBL] [Abstract][Full Text] [Related]
18. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications. Zettler ME Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750 [TBL] [Abstract][Full Text] [Related]
19. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671 [TBL] [Abstract][Full Text] [Related]
20. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]